Researchers have identified variations in levels of certain proteins in the blood after sustained head trauma, which could be measured to confirm concussions.
Highlights: Positive phase 2a clinical trial results for IHL-42X with 60% of trial participants experiencing at least a 55% reduction in the Apnoea Hypopnea.